826 abstracts found.



Results filter

The design of kinase inhibitors as anticancer compounds

Year:

Session type:

Kevin Foote
AstraZeneca, UK

Introduction: MicroRNAs in cancer

Year:

Session type:

Carlos Caldas
Cancer Research UK Cambridge Research Institute, UK

Integrative Oncology in the US- Clinical delivery and unique research

Year:

Session type:

Moshe Frenkel
Integrative Oncology Consultants, Zichron Yaacov, Israel

Evidence based practice: experience of integrating complementary therapies into the cancer service at The Royal Marsden NHS Foundation Trust.

Year:

Session type:

Jeannie Dyer
The Royal Marsden NHS Foundation Trust, London, United Kingdom

Complementary Medicine and Cancer – an overview of integrated approaches

Year:

Session type:

George Lewith
University of Southampton, Southampton, United Kingdom

Introduction: Breast cancer

Year:

Session type:

Alastair Thompson
University of Dundee, UK

Practical aspects of translational research in breast cancer

Year:

Session type:

Colin Purdie
Ninewells Hospital, Dundee, UK

DNA damage response: Mechanisms and relevance for human cancer

Year:

Session type:

Jiri Bartek
Danish Cancer Society, Copenhagen, Denmark

Hypoxia-activated prodrugs for cancer therapy: progress towards an elusive goal

Year:

Session type:

William Denny
University of Auckland, Auckland, New Zealand

Understanding and targeting homologous recombination repair in cancer

Year:

Session type:

Thomas Helleday
University of Oxford, UK

Introduction: Melanoma

Year:

Session type:

Paul Lorigan
University of Manchester, UK

BRAF: melanoma’s first point of vulnerability

Year:

Session type:

Keith Flaherty
Massachusetts General Hospital, Boston, United States

Genetic and Environmental determinants of outcome from melanoma

Year:

Session type:

Julia Newton Bishop
University of Leeds, Leeds, United States

Introduction: Anticancer drug discovery and medicinal chemistry

Year:

Session type:

Roger Griffin
Northern Institute for Cancer Research, University of Newcastle, UK

Introduction: Putting evidence-based policy into practice

Year:

Session type:

Sir Mike Richards
National Cancer Director (England), UK

Translating best evidence into policy

Year:

Session type:

David Currow
Cancer Institute NSW, Alexandria, Australia

Tailoring adjuvant therapy to appropriate patient groups

Year:

Session type:

Jim Cassidy
glasgow university, glasgow, United Kingdom

Towards personalisation in the management of metastatic in colorectal cancer

Year:

Session type:

Eric van Cutsem
University of Leuven, Belgium

Introduction: Development and cancer: what does one teach us about the other?

Year:

Session type:

Mariann Bienz
MRC Laboratory of Molecular Biology, Cambridge, UK

Drosophila as a model system for epithelial tumourigenesis

Year:

Session type:

Barry Thompson
Cancer Research UK, London, United Kingdom

Stem Cell Niche Interactions in Cancer Formation and Metastasis

Year:

Session type:

Joerg Huelsken
EPFL, Lausanne, Switzerland

Targeting the Hedgehog Pathway in Cancer

Year:

Session type:

Frederic de Sauvage
Genentech Inc., South San Francisco, United States

Introduction: Genome stability and DNA repair

Year:

Session type:

Steve Jackson
University of Cambridge, UK

Targeting DNA damage signalling and repair (DDR) for cancer therapy

Year:

Session type:

Nicola Curtin
Newcastle University, Newcastle upon Tyne, United Kingdom

Mismatch repair status in stage II colorectal cancer : Substantially reduced recurrence rate in mismatch repair deficient tumours supports routine testing

Year:

Session type:

Gordon Hutchins1,Katie Southward1,Kelly Handley2,Laura Macgill2,Claire Beaumont1,Jens Stalhschmidt3,Susan Richman1,Matt Seymour4,David Kerr5,Richard Gray2,Phil Quirke1
1Leeds Institute of Molecular Medicine, Leeds, United Kingdom,2Birmingham Clinical Trials Unit, Birmingham, United Kingdom,3Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom,4Cancer Research UK Cancer Centre, Leeds, United Kingdom,5Sidra Medical and Research Centre, Doha, Qatar

A novel colorectal cancer susceptibility SNP in the EIF3H promoter influences patient survival and response to treatment

Year:

Session type:

Christopher Smith1,David Fisher2,Rebecca Harris1,Timothy Maughan3,Shelley Idziaszczyk1,Valentina Moskvina4,James Colley1,Angela Meade2,Cleo Bonnet1,Hannah West1,Richard Kaplan2,The COIN Collaborative Group5,The COIN-B Collaborative Group6,Jeremy Cheadle1
1Institute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, CF14 4XN, United Kingdom,2MRC Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, United Kingdom,3Department of Oncology and Palliative Care, School of Medicine, Cardiff University, Cardiff, CF14 4XN, United Kingdom,4Biostatistics and Bioinfomatics Unit, School of Medicine, Cardiff University, Cardiff, CF14 4XN, United Kingdom,5The COIN Trial steering group and collaborators, -, United Kingdom,6The COIN-B Trial steering group and collaborators, -, United Kingdom

Integrated analysis of genome-wide copy number and expression changes reveals novel genes in oesophageal adenocarcinoma

Year:

Session type:

Xin Yi Goh1,Jonathan Rees1,Anna Paterson1,Suet-Feung Chin2,Maria O'Donovan3,Derek Alderson4,Bauke YIstra5,Carlos Caldas2,Rebecca Fitzgerald1
1Hutchison-MRC Research Centre, Cambridge, United Kingdom,2Cancer Research-UK Cambridge Research Institute, Cambridge, United Kingdom,3Department of Pathology, Addenbrooke’s Hospitals NHS Trust, Cambridge, United Kingdom,4Academic Department of Surgery, Queen Elizabeth Hospital, Birmingham, United Kingdom,5Department of Pathology, VU University Medical Center, Amsterdam, Netherlands

Comparison of Loss of MLH1 and MSH2 Expression Between Oesophageal Cancer and Other Sporadic Cancers of the Gastrointestinal Tract – Relationship With Survival in 1027 Cases

Year:

Session type:

Imran Inam1,Karen Maude2,Lindsay Ward1,Jacinta Murray1,Susan Richman1,Wolfram Mueller3,Abeezar Sarela2,Henry Sue-Ling2,Peter Howdle2,Philip Quirke1,Heike Grabsch1
1Department of Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, Leeds, West Yorkshire, United Kingdom,2Medicine Surgery and Anaesthesia, Leeds Institute of Molecular Medicine, Leeds, West Yorkshire, United States,3Gemeinschaftspraxis Pathologie, Starnberg, Germany

Porfimer sodium photodynamic therapy (PDT) plus stenting versus stenting alone in patients (pts) with advanced or metastatic cholangiocarcinomas and other biliary tract tumours (BTC): a randomised phase lll study (Photostent-02)

Year:

Session type:

S P Pereira1,S K Hughes5,M Roughton5,P O'Donoghue3,H Wasan2,J Valle4,J Bridgewater6
1University College London, The Institute of Hepatology, London, United Kingdom,2Imperial College Healthcare Trust, London, United Kingdom,3University College London Hospital, London, United Kingdom,4Christie Hospital NHS Foundation Trust, University of Manchester, Manchester, United Kingdom,5University College London & Cancer Research UK Cancer, London, United Kingdom,6University College London, Cancer Institute, London, United Kingdom

Thirty-day post-operative mortality after colorectal cancer surgery in England

Year:

Session type:

Eva Morris1,Faye Taylor1,James Thomas1,Phil Quirke1,Paul Finan1,Michel Coleman2,Bernard Rachet2,David Forman1
1University of Leeds, Leeds, United Kingdom,2London School of Hygiene and Tropical Medicine, London, United Kingdom

Clinical development of catumaxomab (Removab) in malignant ascites

Year:

Session type:

Simon Parsons1,Rolf Linke2,Mirko Essing2
1Nottingham City Hospital, Nottingham, United Kingdom,2Fresenius Biotech GmbH, Munich, Germany

Capecitabine/oxaliplatin vs 5FU/oxaliplatin combination chemotherapy in advanced colorectal cancer (aCRC): the MRC COIN trial experience

Year:

Session type:

Ayman Madi1,Richard Wilson2,Richard Adams3,Matt Seymour4,Angela Meade5,Jim Cassidy6,David Fisher5,Sarah Kenny5,Rick Kaplan5,Tim Maughan3
1Freeman Hospital, Newcastle upon Tyne, United Kingdom,2Belfast City Hospital, Belfast, United Kingdom,3Velindre Hospital, Cardiff, United Kingdom,4St James's University Hospital, Leeds, United Kingdom,5Medical Research Council, London, United Kingdom,6The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Integration of miRNA and mRNA expression profiles in breast cancer identifies miRNA associated pathways and prognostic markers

Year:

Session type:

Francesca M. Buffa1,Carme Camps2,Laura Winchester2,Harriet Gee1,Helen Sheldon1,Marian Taylor1,Adrian L. Harris1,Jiannis Ragoussis2
1The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom,2The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

Chemo- and radio-sensitisation of hepatocellular carcinoma by the DNA-dependent protein kinase inhibitor NU7441

Year:

Session type:

Joanne Munck1,Liam Cornell1,Febrina Budhisetiawan1,David Newell1,Julia Bardos2,Helen Reeves1,Nicola Curtin1
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom,2KuDOS Pharmaceuticals Ltd, Cambridge, United Kingdom

Evaluation of a novel Ataxia telangiectasia mutated (ATM) and Rad3-related (ATR) inhibitor, NU6027

Year:

Session type:

Gary Beale1,Amy Peasland1,Lan Wang1,Emily Rowling1,Adam Hopkins1,William Cliby2,Jann Sarkaria2,Richard Edmondson1,Nicola Curtin1
1Newcastle University, Newcastle Upon Tyne, Tyne and Wear, United Kingdom,2Mayo Clinic, Rochester, Minnesota, United States

Induction of a tumor-promoting phenotype in human macrophages by necrotic debris: role of TLR4 and p38 MAP kinase.

Year:

Session type:

Russell Hughes1,Subhra Biswas2,Mary Woodall-Jappe3,Claire Lewis1
1Academic Unit of Inflammation and Tumour Targeting, Sheffield, S. Yorkshire, United Kingdom,2Singapore Immunology Network, Singapore, Singapore,3Eisai Inc, Andover, MA, United States

Discovery of novel Pin1 inhibitors by structure-guided fragment evolution that downregulate cyclin D1 expression in PC-3 prostate cancer cells

Year:

Session type:

Jonathan Moore1,Andrew Potter1,Stuart Ray1,Victoria Oldfield1,Claire Nunns1,Christophe Fromont1,Christopher Northfield1,Louisa Gueritz1,Christopher Bryant1,Simon Scrace1,David Robinson1,Natalia Matassova1,Lisa Baker1,Allan Surgenor1,Pawel Dokurno1,Ben Davis1,Christine Richardson1,James Murray1
1Vernalis, Cambridge, United Kingdom

BACR Translational Research Award: Molecular taxonomy of breast cancer: is there a gold standard?

Year:

Session type:

Britta Weigelt1,Alan Mackay2,Roger A’hern3,Rachael Natrajan2,David SP Tan2,Mitch Dowsett2(4),Mitch Dowsett2(4),Mitch Dowsett2(4)

1

Cancer Research UK London Research Institute, UK,2The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK,3
,Cancer Research UK Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, UK,4
,Academic Department of Biochemistry, Royal Marsden Hospital, London, UK


What reasons do patients give for declining or participating in early phase cancer trials?

Year:

Session type:

Susan Catt1,Carolyn Langridge1,Valerie Jenkins1,Denis Talbot2,Lesley Fallowfield1
1CRUK Psychosocial Oncology Group, Brighton & Sussex Medical School, Brighton, United Kingdom,2Oxford Radcliffe Hospitals NHS Trust, Oxford, United Kingdom

Physical Activity Intervention in Cancer Survivors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Year:

Session type:

Judy Ho1,Bryant Hui1,Daniel Fong2,Duncan Macfarlane3,Antoinette Lee4,Sharron Leung2,Ester Cerin3,Wynnie Chan1,Ivy Leung5,Sharon Lam6,Aliki Taylor7,KK Cheng8
1Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong,2Department of Nursing Studies, The University of Hong Kong, Hong Kong, Hong Kong,3Institute of Human Performance, The University of Hong Kong, Hong Kong, Hong Kong,4Department of Psychiatry, The University of Hong Kong, Hong Kong, Hong Kong,5Queen Elizabeth Hospital, Kowloon, Hong Kong,6Baptist University, Kowloon, Hong Kong,7Agmen Limited, Uxbridge, United Kingdom,8Dept of Public Health and Epidemiology, University of Birmingham, Birmingham, United Kingdom

The prognosis in palliative care study (PiPS)

Year:

Session type:

Bridget Gwilliam1,Matthew Gittens2,Chris Roberts2,Chris Todd2,Vaughan Keeley3,Stephen Barclay4,Laura Kelly5,Patrick Stone1
1St Georges's, University of London, London, United Kingdom,2University of Manchester, Manchester, United Kingdom,3Derby Hospitals Foundation Trust, Derby, United Kingdom,4University of Cambridge, Cambridge, United Kingdom,5East Surrey Hospital, Redhill, United Kingdom

Which research priorities are defined by young people with cancer- second consultation by the National Cancer Research Institute’s Teenage and Young Adult Core Consumer Group

Year:

Session type:

Lorna Fern1,James Ashton4,Katie Brooman4,Tom Grew4,Carol Irving2,Hannah Millington4,Carol Starkey4,David Wright3,Jeremy Whelan1
1University College Hospitals, London, United Kingdom,2Leeds Teaching Hospitals NHS Trusts, Leeds, United Kingdom,3Clatterbridge Centre for Oncology NHS Foundation Trust, Liverpool, United Kingdom,4NCRI Teenage & Young Adult Core Consumer Group, London, United Kingdom

Functional characterization of SET8 in prostate cancer cell lines

Year:

Session type:

Dhuha Alkharaif1,Kelly Armstrong1,Craig Robson1
1Newcastle University, Newcastle Upon Tyne, United Kingdom

Cancer death data as part of the National End of Life Care Intelligence Network Website 

Year:

Session type:

Andy Pring1,Kate Ruth1,Matthew Iles1,Luke Hounsome1,Veronique Poirier1,Julia Verne1
1South West Public Health Observatory, Bristol, United Kingdom

Targeted intra-operative radiotherapy (TARGIT) for early stage breast cancer: the TARGIT-A trial at 10 years maximum follow up.

Year:

Session type:

Jayant Vaidya1,Jeffrey Tobias1,Mohammed Keshtgar1,David Joseph2,Frederik Wenz3,Max Bulsara4,Christobel Saunders2,Norman Williams1,Michael Baum1
1UCL, London, United Kingdom,2Sir Charles Gairdner Hospital, Perth, Australia,3Universitätsmedizin Mannheim, Mannheim, Germany,4University of Notre Dame, Fremantle, Australia

Survival after first course of palliative radiotherapy: An observational cohort study

Year:

Session type:

Matt Williams1,David Woolf1,Rob Hughes1,Jane Maher1,Jeanette Dickson1
1Mount Vernon Cancer Centre, London, United Kingdom

Functional evaluation of homologous recombination pathway in epithelial ovarian cancer and the potential for targeted chemotherapy with PARP inhibitors

Year:

Session type:

Asima Mukhopadhyay1,Sandra Soohoo1,Bisha Uzir1,Ahmed Elattar1,Sarah Wilkinson1,Aiste Cerbinskaite1,Nicola Curtin1,Richard Edmondson2
1Northern Institute for Cancer Research, Newcastle university, United Kingdom,2Northern Gynaecological Oncology Centre, Gateshead, United Kingdom

Four-fold increase in recruitment of cancer patients to NCRN portfolio studies between 2001 and 2010: a tale of investment bringing returns. 

Year:

Session type:

David Cameron2,Matt Cooper1,Bob Haward1,Rick Kaplan1,Karen Poole1,Nancy Lester3,Ruth McLaren1,Rachel Moser1,Mahesh Parmar1,Rachel Moser1,Maxine Stead3,Peter Selby3
1NIHR NCRN Co-ordinating centre, Leeds University, LEEDS, United Kingdom,2Universtiy of Edinburgh, EDINBURGH, United Kingdom,3NIHR CRN Co-ordinating Centre, Leeds University, LEEDS, United Kingdom,4MRC Clinical Trials Unit, LONDON, United Kingdom

MGMT methylation is strongly associated with and may precede IDH1/IDH2 mutations in adult astrocytic and oligodendroglial tumours

Year:

Session type:

Shani Mulholland1,Deborah S Malley1,Rifat Hamoudi1,Sylvia Kocialkowski1,Danita Pearson1,V.Peter Collins1,Koichi Ichimura1
1Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom

The primary health and supportive care needs of long-term cancer survivors

Year:

Session type:

Sian Harrison1,Eila Watson2,Nada Khan1,Alison Ward1,Monica Roche3,David Forman4,Peter Rose1
1Oxford University, Oxford, United Kingdom,2Oxford Brookes University, Oxford, United Kingdom,3Oxford Cancer Intelligence Unit, Oxford, United Kingdom,4Northern and Yorkshire Cancer Registry and Information Service, Leeds, United Kingdom